Plus Therapeutics Provides Updates on ReSPECT™ Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
November 19, 2022 08:24 ET
|
Plus Therapeutics Inc.
ReSPECT-GBM clinical trial of rhenium (186Re) obisbemeda in recurrent glioblastoma continues to demonstrate safety and overall survival correlates with radiation dose to tumor ReSPECT-GBM Phase 2...
Plus Therapeutics to Provide Update on ReSPECT™ Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
November 02, 2022 07:00 ET
|
Plus Therapeutics Inc.
Recurrent glioblastoma and leptomeningeal metastases data have been selected for oral presentations Pediatric brain cancer plans will be shared via poster session AUSTIN, Texas, Nov. 02, 2022 ...
Plus Therapeutics Announces Selection of “Rhenium (186Re) Obisbemeda” as International Non-Proprietary Name for 186RNL
October 26, 2022 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...
Plus Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
October 20, 2022 16:05 ET
|
Plus Therapeutics Inc.
Awarded $17.6 million Product Development Research grant by the Cancer Prevention & Research Institute of Texas (CPRIT) to fund 186RNL development for leptomeningeal metastases (LM) ...
Plus Therapeutics Presents Preliminary Safety and Feasibility Data from ReSPECT-LM Clinical Trial at the European Association of Nuclear Medicine Congress
October 19, 2022 07:00 ET
|
Plus Therapeutics Inc.
ReSPECT-LM Phase 1 clinical trial selected as TOP Trials Oral Presentation Treatment was well tolerated without dose limiting toxicities and all patients showed a decrease in spinal fluid tumor...
Plus Therapeutics to Present at the ThinkEquity Conference
October 18, 2022 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and...
Plus Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on October 20, 2022
October 06, 2022 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...
Plus Therapeutics Announces Patient Webinar in Recognition of Breast Cancer Awareness Month
October 05, 2022 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...
Plus Therapeutics to Share Data in Oral Presentations from Ongoing ReSPECT™ Clinical Trials at the 35th Annual Congress of the European Association of Nuclear Medicine
October 04, 2022 07:15 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...
Plus Therapeutics Executes $17.6 Million Award Contract with Cancer Prevention & Research Institute of Texas
September 22, 2022 07:00 ET
|
Plus Therapeutics Inc.
Initial CPRIT grant funds of $1.9 million to be disbursed to Company by October 31, 2022 CPRIT grant to support majority of 186RNL targeted therapeutic development costs for leptomeningeal metastases...